BioNTech's Profit Turnaround Rests on One-Off Effects as Oncology Bets Face Their First Real Test
Published on 11/04/2026 at 02:41 | Editorial boerse-global.de
BioNTech is back in the black, but the headline number flatters a business still searching for a durable earnings base. The German biotech posted an IFRS net profit of EUR 184.5 million for the third quarter of 2026, reversing a loss of EUR 28.7 million a year earlier — a swing that Reuters attributes chiefly to the absence of hefty one-off charges tied to legal disputes rather than to any step-change in operations.
Strip those effects out and the picture darkens. Adjusted net profit fell to EUR 440.9 million from EUR 752.5 million in the prior-year quarter, squeezed by weaker vaccine demand and rising research spending. Adjusted earnings per share came in at EUR 1.76, which still cleared analyst forecasts — a beat, but not growth.
A revenue line still anchored to a shrinking franchise
Quarterly revenue reached EUR 1.29 billion, ahead of the EUR 1.05 billion consensus but down 15% year on year. Management pointed squarely at softer demand for COVID-19 shots, and that drag continues to define the near-term top line. Progress in oncology has yet to offset it.
On the full-year view, BioNTech now guides to revenue of EUR 1.7 billion to EUR 1.9 billion, lifting the floor from EUR 1.6 billion while leaving the ceiling untouched. Finance chief RamĂłn Zapata said the quarterly results had pushed the annual expectation toward the upper end of the previously stated range, with investment continuing to concentrate on priority oncology programmes.
Should investors sell immediately? Or is it worth buying BioNTech?
Where the money is going
Research and development under IFRS climbed to EUR 748.1 million from EUR 564.8 million, or EUR 578.5 million on an adjusted basis. The adjusted R&D forecast of EUR 2.0 billion to EUR 2.3 billion remains unchanged. That spending reflects a company still mid-transformation, aiming to bring several products to market — a cost base that makes a single quarter's profit a poor gauge of lasting financial health. Over the first nine months of 2026, BioNTech recorded a net loss of EUR 1,168.2 million, wider than the EUR 831.1 million shortfall in the same period a year earlier.
Cash remains abundant: cash, cash equivalents and securities investments totalled EUR 16.2 billion as of 30 September, giving the company ample room to fund its pipeline.
Lung data encourage, breast data counsel patience
The clinical scorecard is mixed. In ROSETTA Lung-107, a Phase 2 study of pumitamig combined with docetaxel in metastatic non-small cell lung cancer, the confirmed objective response rate came in at 36.7%, according to the partners. The trial enrolled patients who had already received first-line immunotherapy plus chemotherapy; BioNTech and Bristol Myers Squibb, presenting the global data together, called the anti-tumour activity encouraging and the safety profile manageable.
A separate programme drew a more guarded read. Roughly a week earlier, BioNTech and DualityBio reported results for trastuzumab pamirtecan in metastatic breast cancer. The Phase 3 DYNASTY-Breast02 trial met its primary endpoint, but the statistically significant improvement in progression-free survival was only modest by the companies' own account. The partners also flagged more frequent interstitial lung disease than in earlier studies, including a small share of severe and fatal cases. Overall survival data were not yet mature, and the companies said the benefit could be limited in the existing treatment landscape as they weigh next steps.
BioNTech at a turning point? This analysis reveals what investors need to know now.
On the positive side of the ledger, gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous NSCLC, per company figures — support for the oncology strategy, though not yet a substitute for sustained product revenue.
The quarter thus cuts two ways: BioNTech beat expectations and nudged up the bottom of its revenue range, even as adjusted profit slid and the nine-month loss deepened. Whether the return to profit proves durable depends less on the legal charges that flattered this quarter than on whether the pipeline can start paying for itself.
Ad
BioNTech Stock: New Analysis - 4 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
